Effect of Proton Pump Inhibitors on Endothelial Function

Inclusion Criteria: * Healthy male or female volunteers aged 18 to 75 years (n=10) or male or female volunteers with a history of coronary or peripheral artery disease (n=10) * Able to understand the nature of the study and to give written informed consent * Able to communicate well with the investigator himself or his/her representatives * Body Mass Index between 18 kg/m\^2 and 35 kg/m\^2 at the screening visit * Creatinine \<1.5, and liver enzymes \<2x normal, with all laboratory tests considered normal or of no significant clinical relevance to the study by the investigator Exclusion Criteria: * Contra-indication to proton pump inhibitor treatment * Current treatment with PPI or H2 antagonist, and not able to tolerate withdrawal or washout of medication. * Current or historical evidence of clinically severe cardiovascular, neurological, hematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolic or psychiatric disease. * Any other acute or chronic disease which could influence the volunteer's health and/or the study results * Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or hernia repair * Use of enzyme inducers or enzyme inhibitor drugs within the last three months before the first drug administration * Participation in another ongoing clinical trial * Past or current drug exposure amounting to drug abuse or addiction * Past or current alcohol exposure amounting to alcohol abuse or addiction (i.e. \> 28 units per week for males, where 1 unit = one measure of spirit (25 mL), one glass of wine (125 mL) or 1/2 pint beer) * Donation of blood or any other major blood loss (\>500 mL) within three months before the study * Unwilling or unable to comply with the study protocol for any reason or in the opinion of the investigator should not participate in the study * Positive test for hepatitis B surface antigen, hepatitis C antibody, HIV-1 or HIV-2 antibody at screening * Known allergy or intolerance to any other compound in the study drug or any other closely related compound